Edyta Blaszczyk1,2, Jan Gröschel1,2, Jeanette Schulz-Menger3,4. 1. Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center a joint cooperation between the Charité - Universitätsmedizin Berlin, Department of Internal Medicine and Cardiology and the Max-Delbrueck Center for Molecular Medicine, and HELIOS Klinikum Berlin Buch, Department of Cardiology and Nephrology, Berlin, Germany. 2. DZHK (German Centre for Cardiovascular Research), Berlin, Germany. 3. Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center a joint cooperation between the Charité - Universitätsmedizin Berlin, Department of Internal Medicine and Cardiology and the Max-Delbrueck Center for Molecular Medicine, and HELIOS Klinikum Berlin Buch, Department of Cardiology and Nephrology, Berlin, Germany. jeanette.schulz-menger@charite.de. 4. DZHK (German Centre for Cardiovascular Research), Berlin, Germany. jeanette.schulz-menger@charite.de.
Abstract
PURPOSE OF REVIEW: This review aims to outline the utility of cardiac magnetic resonance (CMR) in patients with different types of muscular dystrophies for the assessment of myocardial involvement, risk stratification and in guiding therapeutic decisions. RECENT FINDINGS: In patients suffering from muscular dystrophies (MD), even mild initial dysfunction may lead to severe heart failure over a time course of years. CMR plays an increasing role in the diagnosis and clinical care of these patients, mostly due to its unique capability to precisely characterize subclinical and progressive changes in cardiac geometry, function in order to differentiate myocardial injury it allows the identification of inflammation, focal and diffuse fibrosis as well as fatty infiltration. CMR may provide additional information in addition to the physical examination, laboratory tests, ECG, and echocardiography. Further trials are needed to investigate the potential impact of CMR on the therapeutic decision-making as well as the assessment of long-term prognosis in different forms of muscular dystrophies. In addition to the basic cardiovascular evaluation, CMR can provide a robust, non-invasive technique for the evaluation of subclinical myocardial tissue injury like fat infiltration and focal and diffuse fibrosis. Furthermore, CMR has a unique capability to detect the progression of myocardial tissue damage in patients with a preserved systolic function.
PURPOSE OF REVIEW: This review aims to outline the utility of cardiac magnetic resonance (CMR) in patients with different types of muscular dystrophies for the assessment of myocardial involvement, risk stratification and in guiding therapeutic decisions. RECENT FINDINGS: In patients suffering from muscular dystrophies (MD), even mild initial dysfunction may lead to severe heart failure over a time course of years. CMR plays an increasing role in the diagnosis and clinical care of these patients, mostly due to its unique capability to precisely characterize subclinical and progressive changes in cardiac geometry, function in order to differentiate myocardial injury it allows the identification of inflammation, focal and diffuse fibrosis as well as fatty infiltration. CMR may provide additional information in addition to the physical examination, laboratory tests, ECG, and echocardiography. Further trials are needed to investigate the potential impact of CMR on the therapeutic decision-making as well as the assessment of long-term prognosis in different forms of muscular dystrophies. In addition to the basic cardiovascular evaluation, CMR can provide a robust, non-invasive technique for the evaluation of subclinical myocardial tissue injury like fat infiltration and focal and diffuse fibrosis. Furthermore, CMR has a unique capability to detect the progression of myocardial tissue damage in patients with a preserved systolic function.
Authors: Shiro Nakamori; An H Bui; Jihye Jang; Hossam A El-Rewaidy; Shingo Kato; Long H Ngo; Mark E Josephson; Warren J Manning; Reza Nezafat Journal: J Magn Reson Imaging Date: 2017-07-24 Impact factor: 4.813
Authors: Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham Journal: Circulation Date: 2015-05-05 Impact factor: 29.690
Authors: Marthe A J Becker; Jan H Cornel; Peter M van de Ven; Albert C van Rossum; Cornelis P Allaart; Tjeerd Germans Journal: JACC Cardiovasc Imaging Date: 2018-04-18
Authors: Katherine C Wu; Robert G Weiss; David R Thiemann; Kakuya Kitagawa; André Schmidt; Darshan Dalal; Shenghan Lai; David A Bluemke; Gary Gerstenblith; Eduardo Marbán; Gordon F Tomaselli; João A C Lima Journal: J Am Coll Cardiol Date: 2008-06-24 Impact factor: 24.094
Authors: Sven Dittrich; Erika Graf; Regina Trollmann; Ulrich Neudorf; Ulrike Schara; Antje Heilmann; Maja von der Hagen; Brigitte Stiller; Janbernd Kirschner; Robert Dalla Pozza; Wolfgang Müller-Felber; Katja Weiss; Katja von Au; Markus Khalil; Reinald Motz; Christoph Korenke; Martina Lange; Ekkehard Wilichowski; Joseph Pattathu; Friedrich Ebinger; Nicola Wiechmann; Rolf Schröder Journal: Orphanet J Rare Dis Date: 2019-05-10 Impact factor: 4.123
Authors: Ankur Gulati; Andrew Jabbour; Tevfik F Ismail; Kaushik Guha; Jahanzaib Khwaja; Sadaf Raza; Kishen Morarji; Tristan D H Brown; Nizar A Ismail; Marc R Dweck; Elisa Di Pietro; Michael Roughton; Ricardo Wage; Yousef Daryani; Rory O'Hanlon; Mary N Sheppard; Francisco Alpendurada; Alexander R Lyon; Stuart A Cook; Martin R Cowie; Ravi G Assomull; Dudley J Pennell; Sanjay K Prasad Journal: JAMA Date: 2013-03-06 Impact factor: 56.272